BioSpecifics Technologies (BioSpecifics Technologies) Inventory-to-Revenue : 0.00 (As of Sep. 2020)

View and export this data going back to 1991. Start your Free Trial

What is BioSpecifics Technologies Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. BioSpecifics Technologies's Average Total Inventories for the quarter that ended in Sep. 2020 was $0.00 Mil. BioSpecifics Technologies's Revenue for the three months ended in Sep. 2020 was $11.26 Mil. BioSpecifics Technologies's Inventory-to-Revenue for the quarter that ended in Sep. 2020 was 0.00.

BioSpecifics Technologies's Inventory-to-Revenue for the quarter that ended in Sep. 2020 stayed the same from Jun. 2020 (0.00) to Jun. 2020 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

BioSpecifics Technologies Inventory-to-Revenue Historical Data

The historical data trend for BioSpecifics Technologies's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioSpecifics Technologies Inventory-to-Revenue Chart

BioSpecifics Technologies Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Inventory-to-Revenue

Get a 7-Day Free Trial

BioSpecifics Technologies Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Inventory-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of BioSpecifics Technologies's Inventory-to-Revenue

For the Biotechnology subindustry, BioSpecifics Technologies's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioSpecifics Technologies's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioSpecifics Technologies's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where BioSpecifics Technologies's Inventory-to-Revenue falls into.

BioSpecifics Technologies Inventory-to-Revenue Calculation

BioSpecifics Technologies's Inventory-to-Revenue for the fiscal year that ended in Dec. 2019 is calculated as

	Inventory-to-Revenue (A: Dec. 2019 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2018 )	+	Total Inventories (A: Dec. 2019 ))	/	count )	/	Revenue (A: Dec. 2019 )
=	( (0	+	0)	/	1 )	/	38.188
=	0					/	38.188
=	0.00

BioSpecifics Technologies's Inventory-to-Revenue for the quarter that ended in Sep. 2020 is calculated as

	Inventory-to-Revenue (Q: Sep. 2020 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Jun. 2020 )	+	Total Inventories (Q: Sep. 2020 ))	/	count )	/	Revenue (Q: Sep. 2020 )
=	( (0	+	0)	/	1 )	/	11.256
=	0					/	11.256
=	0.00

BioSpecifics Technologies (NAS:BSTC) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

BioSpecifics Technologies's Days Inventory for the three months ended in Sep. 2020 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Sep. 2020 )	/	Cost of Goods Sold (Q: Sep. 2020 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

BioSpecifics Technologies's Inventory Turnover for the quarter that ended in Sep. 2020 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Sep. 2020 )	/	Average Total Inventories (Q: Sep. 2020 )
	=	0	/	0
	=

BioSpecifics Technologies Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of BioSpecifics Technologies's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

BioSpecifics Technologies (BioSpecifics Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioSpecifics Technologies Corp (NAS:BSTC) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

35 Wilbur Street, Lynbrook, NY, USA, 11563

Website

https://www.biospecifics.com

BioSpecifics Technologies Corp is a biopharmaceutical company that specializes in collagenase for multiple indications. Injectable collagenase is marketed in various geographic regions, including the U.S., the EU, and Australia, under the Xiaflex name. The targeted diseases are Dupuytren's contracture and Peyronie's disease. The company is also researching the development of Xiaflex as a solution for new potential indications, such as uterine fibroids, adhesive capsulitis, cellulite, lateral hip fat, plantar fibromatosis, and human and canine lipomas.

Executives

Paul Gitman	director	167 EXECUTIVE DRIVE MANHASSET HILLS NY 11040
Michael Schamroth	director	191 MEADOWVIEW AVENUE HEWLETT NY 11557
Toby Wegman	director, 10 percent owner	4092 BOCAIRE BLVD. BOCA RATON FL 33487
Mark N Wegman	director	43 OVERLOOK ROAD OSSINING NY 10562
Jennifer M Chao	director	7 PURITAN WOODS ROAD, RYE NY 10580
Joseph Truitt	director, officer: Chief Executive Officer	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Michael A. Sherman	director	3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Fishman Corey N.	director	DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
Patrick Hutchison	officer: Chief Financial Officer	C/O BIOSPECIFICS TECHNOLOGIES CORP 2 RIGHTER PARKWAY SUITE 200 WILMINGTON DE 19803
J Kevin Buchi	director, officer: Chief Executive Officer	41 MOORES ROAD, FRAZER PA 19355
Patrick M Caldwell	officer: Principal Financial Officer	C/O PROTINE DESIGN LAB 532 BELLA CALAIS WAY SAN JOSE CA 94138
Jyrki Mattila	director	AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Ronald Edward Law	officer: SVP Business Development	23733 N. LOOKOUT PT. ROAD, LAKE BARRINGTON IL 60010
Thomas Wegman	director, 10 percent owner, officer: President	1764 BRIAR PLACE MERRICK NY 11566
Estate Of Edwin H. Wegman	10 percent owner	4092 BOCAIRE BLVD. BOCA RATON FL 33487